Previous studies by Coral-Vazquez et al [
1] have shown that
Scgd−/− mouse develop skeletal muscle dystrophy and cardiomyopathy; histopathology demonstrated focal areas of necrosis in cardiac and skeletal muscle. Premature death begins to occur around 6 months of age. To our knowledge, this is the first in vivo imaging study examining the cardiac morphology and function of the
Scgd−/− mouse. Our results confirm the previous assertion that the disruption of δ-sarcoglycan gene causes severe adverse response in cardiac function and morphology in the
Scgd−/− mouse.
The utility of cine MRI in the assessment of cardiac morphology and function in myopathic mouse models has been previously described [
6–
7]. Typically in the
mdx mouse, a commonly used model of human muscular dystrophy, the systolic function is found to be normal even at 8 months of age [
7]. In contrast, we found that the 8 month old
Scgd−/− mouse had reduced LV ejection fraction when compared to wild type. We also found that
Scgd−/− had significant RV dilatation and reduced RV ejection, an observation that has not been previously reported in
Scgd−/− mice. Coral-Vazquez et al [
1] found severe necrosis in the young
Scgd−/− diaphragm. The diaphragm muscle weakness could lead to pulmonary dysfunction and RV dilatation. Interestingly pulmonary dysfunction is common in the advanced stages of Duchenne muscular dystrophy and limb-girdle muscular dystrophy patients [
16–
18].
In addition to cine MRI we performed delayed enhanced MR (MDE) imaging and myocardial tagging. Only one out of five
Scgd−/− mice showed positive MDE. A mild increase in signal intensity was seen in the anterior lateral and septal wall at basal level (). The diffused pattern of signal distribution was markedly different to the well defined, high contrasted hyper enhancement typically seen in an ischemia reperfusion model. The diffused pattern of myocardial hyper enhancement is typical in older patients with muscular dystrophy and is well described in literature [
19–
24].
Due to long T1 relaxation times at 7 Tesla, myocardial tags persist throughout the cardiac cycle allowing accurate measurement of temporal evolution of myocardial strain in mice. Our results showed significant difference in Ecc between the
Scgd−/− and WT mice. Progressive myocardial strain impairment has been observed in Duchenne muscular dystrophic patients [
25]. In our experience, myocardial strain impairment precedes global dysfunction and could serve as an early sign of cardiomyopathy in these patients. We also measured a significantly high cross correlation delay, XCD in the
Scgd−/− mice (55±3ms vs. 8±5ms). Studies with Doppler tissue imaging and phase contrast MRI has shown that XCD is superior to existing parameters at discriminating patients with left ventricular dyssynchrony from those with normal function [
14–
15]. The left ventricular dyssynchrony in
Scgd−/− mice correlates well with Coral-Vazquez et al [
1]'s observations in ECG characteristics of these mice. They found that ventricular excitation (QRS amplitude and duration) was markedly perturbed in Scgd
−/− compared to WT consistent with the idea that fibrotic lesions in
Scgd−/− underlie abnormal activation.
In summery, 8 months old Scgd−/− mice demonstrated both RV and LV dysfunction, RV dilatation, myocardial strain impairment and LV dyssynchrony. This study shows that myocardial strain quantified by MR tagging is a sensitive measure of regional impairment in these mice. Impaired myocardial strain points to damaged tissue structure. Since contraction induced myocardial injury plays a significant role in the pathobiology of this disease, it is important to be able to quantify this phenomenon non-invasively. Results of this study indicate that circumferential strain could be used as a surrogate marker of the disease severity. This could be particularly important in the pre-clinical assessment of novel therapeutic agents. On going research in this area at our center include longitudinal MRI study of Scgd−/− mice treated with a TGFβ blocking agent, Losartan. It is hoped that results of this study will further reveal the underlying pathobiology of the impaired function in these mice.
Studies have repeatedly shown that cardiac assessment by standard echocardiographic imaging is inadequate for detecting the presence of heart disease in the first decade of life[
25–
26]. Indeed, one of the limitations to assessing therapeutic effect in the early stages of cardiomyopathy has been the lack of sensitive diagnostic tools to identify cardiac dysfunction in the young patient. Myocardial strain can be assessed in routine clinical MRI exams. Detection of strain abnormalities might provide a useful surrogate index to assess therapeutic efficacy.